Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512889 · ClinicalTrials.gov registry record · Phase 1
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00512889 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 9 participants.
The verdict
NCT00512889, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Cytotoxic T lymphocytes (CTL) are cells of the immune system that can fight infections and cancer. These CTL can be manipulated in the laboratory so that they can target an individual's cancer. PURPOSE: This early phase trial is studying the feasibility and side effects of intravenous infusions of CTL generated in the laboratory. To produce the CTL, the study participant's own immune cells are collected by a procedure called a leukapheresis. The cells then undergo laboratory processing for three weeks. Part of this processing includes mixing the patients immune cells with a new kind of cell that has some extra genes added to it. These extra genes are to "teach" the participant's own immune cells to become anti-tumor CTL that can attack the melanoma.
Interventions
- DRUG GM-CSF
- BIOLOGICAL therapeutic autologous lymphocytes
- GENETIC Use of an artificial antigen presenting cell (aAPC) to generate CTL
- RADIATION Irradiation of cutaneous tumor lesion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512889
The ClinicalTrials.gov registry entry for NCT00512889 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which GM-CSF is the first listed.
NCT00512889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512889 about?
NCT00512889 is a clinical study titled "Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma". RATIONALE: Cytotoxic T lymphocytes (CTL) are cells of the immune system that can fight infections and cancer. These CTL can be manipulated in the laboratory so that they can target an individual's cancer. PURPOSE: This early phase trial is studying the feasibility and side effects of intravenous in...
What is the current status of trial NCT00512889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-08. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00512889?
The interventions under investigation include: GM-CSF (DRUG), therapeutic autologous lymphocytes (BIOLOGICAL), Use of an artificial antigen presenting cell (aAPC) to generate CTL (GENETIC), Irradiation of cutaneous tumor lesion (RADIATION).
Who is sponsoring clinical trial NCT00512889?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.